Can dexamethasone be given to a pregnant woman at 35 weeks and 5 days gestation with suspected intrauterine growth restriction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Dexamethasone at 35 Weeks 5 Days with Suspected IUGR

Yes, dexamethasone can and should be given at 35 weeks 5 days gestation with suspected IUGR if delivery is anticipated within 7 days and the patient has not received a prior course of antenatal corticosteroids.

Primary Recommendation

The Society for Maternal-Fetal Medicine (SMFM) provides clear guidance on this clinical scenario. For pregnancies between 34 0/7 and 36 6/7 weeks of gestation who are at high risk of preterm delivery within 7 days, a single course of antenatal corticosteroids (2 doses of 12 mg intramuscular betamethasone 24 hours apart, or equivalent dexamethasone dosing) is recommended 1. This is a GRADE 1A recommendation, representing the highest level of evidence.

Key Clinical Decision Points

When to Give Steroids in IUGR at This Gestational Age:

  • Delivery anticipated within 7 days: This is the critical criterion. At 35+5 weeks with IUGR, you must assess whether delivery is imminent 2
  • No prior course received: The patient should not have received antenatal corticosteroids previously 1
  • No contraindications present: Specifically, avoid in patients with pregestational diabetes mellitus due to increased risk of neonatal hypoglycemia 2

IUGR-Specific Considerations:

The SMFM FGR guidelines specifically address corticosteroid use in growth-restricted fetuses. In the setting of reversed end-diastolic velocity on umbilical artery Doppler, hospitalization and administration of antenatal corticosteroids is recommended 1. This represents a scenario where delivery is clearly anticipated soon.

For IUGR at 35+5 weeks, your decision algorithm should be:

  1. Assess umbilical artery Doppler status:

    • Normal or decreased end-diastolic velocity → Plan delivery at 37 weeks 1
    • Absent end-diastolic velocity → Plan delivery at 33-34 weeks (already past this window) 1
    • Reversed end-diastolic velocity → Immediate hospitalization, steroids, and consideration of delivery 1

  2. Determine delivery timing:

    • If delivery will occur within 7 days → Give steroids
    • If delivery not anticipated before 37 weeks → Do not give steroids 2

Important Caveats and Pitfalls

The IUGR Paradox:

While steroids are beneficial for neonatal respiratory outcomes, there is legitimate concern about their use in IUGR. Animal studies show that dexamethasone can worsen placental function and reduce placental VEGF expression 3. However, the clinical benefits of preventing respiratory distress syndrome outweigh theoretical concerns when delivery is imminent 1.

Avoid Overuse:

Do not give corticosteroids to patients with a low likelihood of delivery before 37 weeks 2. This is a GRADE 1B recommendation. At 35+5 weeks, if the IUGR is mild (estimated fetal weight 3rd-10th percentile with normal Doppler), delivery may be planned for 38-39 weeks 1, making steroids unnecessary.

Diabetes Contraindication:

Absolutely avoid late preterm corticosteroids in patients with pregestational diabetes mellitus due to significantly increased risk of neonatal hypoglycemia 2. This is a firm contraindication.

Doppler Studies Are Essential:

The evidence shows that antenatal steroids do not adversely affect Doppler measurements 4, so you can continue to use umbilical artery Doppler for surveillance even after steroid administration. This is clinically important for ongoing management decisions.

Dosing Specifics

Standard dosing options 1, 5:

  • Betamethasone: 12 mg intramuscularly every 24 hours for 2 doses (preferred based on ALPS trial data)
  • Dexamethasone: 6 mg intramuscularly every 12 hours for 4 doses (alternative)

Recent evidence suggests 5 mg dexamethasone may be noninferior to 6 mg 6, though the standard 6 mg dose remains guideline-recommended.

Counseling Requirements

You must thoroughly counsel the patient regarding potential risks and benefits, emphasizing that long-term risks remain uncertain 2. This is a GRADE 1C recommendation. Discuss that while steroids reduce respiratory complications, there are concerns about metabolic programming and potential long-term neurodevelopmental effects 7.

Bottom Line Algorithm

At 35 weeks 5 days with suspected IUGR:

  1. Confirm IUGR diagnosis with ultrasound (EFW <10th percentile) 1
  2. Obtain umbilical artery Doppler 1
  3. Assess delivery timing based on severity and Doppler findings
  4. If delivery anticipated within 7 days AND no prior steroids AND no pregestational diabetes → Give betamethasone 12 mg IM × 2 doses 24 hours apart 2, 1
  5. If delivery not anticipated until ≥37 weeks → Do not give steroids 2

References

Related Questions

What is the recommended rescue dose of dexamethasone (corticosteroid) for pregnant women?
Is dexamethasone (corticosteroid) safe to use during pregnancy?
Do you administer dexamethasone (corticosteroid) in a preterm labor patient at 35 weeks gestation?
What is the most appropriate management for a 30-week gestation patient presenting with preterm labor, characterized by abdominal pain, regular contractions, 2 cm cervical dilation, and 80% effacement, with a normal fetal heart rate and no signs of leaking or bleeding?
What is the recommended dexamethasone dosing for fetal lung maturation in pregnant women at risk of preterm birth before 34 weeks?
What is the recommended mesalazine (5‑ASA) dosage for ulcerative colitis based on disease extent (proctitis, left‑sided colitis, extensive or pancolitis)?
What are the causes of concurrent hypokalemia and hyponatremia?
Does primary hyperaldosteronism cause hypokalemia, hyponatremia, and hypertension?
How should potassium supplementation be managed in a patient taking telmisartan 40 mg once daily who has mild hypokalemia (serum potassium ≈3.3 mmol/L) and normal renal function?
What is the appropriate loading dose of meropenem for a patient with sepsis and acute kidney injury?
What findings should be documented during a head-to-toe examination of a trauma patient?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.